TH starting another ThGRF Phase II

Theratechnologies (TSE:TH) is beginning a double-blind, placebo-controlled, U.S. Phase II trial of its ThGRF (TH 907) growth-hormone releasing factor analog in up to 45 patients with Type II diabetes....